Application of physiologically based pharmacokinetic modeling in predicting drug–drug interactions for sarpogrelate hydrochloride in humans

References

• HuangSMPBPK as a tool in regulatory reviewBiopharm Drug Dispos2012332515222351604
   PubMed Web of Science ®Google Scholar
• JonesHRowland-YeoKBasic concepts in physiologically based pharmacokinetic modeling in drug discovery and developmentCPT Pharmacometrics Syst Pharmacol20132e6323945604
   PubMedGoogle Scholar
• LeongRVieiraMLZhaoPRegulatory experience with physiologically based pharmacokinetic modeling for pediatric drug trialsClin Pharmacol Ther201291592693122472993
   PubMed Web of Science ®Google Scholar
• RowlandMPeckCTuckerGPhysiologically-based pharmacokinetics in drug development and regulatory scienceAnnu Rev Pharmacol Toxicol201151457320854171
   PubMed Web of Science ®Google Scholar
• SinhaVZhaoPHuangSMZinehIPhysiologically based pharmacokinetic modeling: from regulatory science to regulatory policyClin Pharmacol Ther201495547848024747236
   PubMed Web of Science ®Google Scholar
• ZhaoPRowlandMHuangSMBest practice in the use of physiologically based pharmacokinetic modeling and simulation to address clinical pharmacology regulatory questionsClin Pharmacol Ther2012921172022713733
   PubMed Web of Science ®Google Scholar
• DoggrellSASarpogrelate: cardiovascular and renal clinical potentialExpert Opin Investig Drugs2004137865874
   PubMed Web of Science ®Google Scholar
• MiyazakiMHigashiYGotoCSarpogrelate hydrochloride, a selective 5-HT2A antagonist, improves vascular function in patients with peripheral arterial diseaseJ Cardiovasc Pharmacol200749422122717438407
   PubMed Web of Science ®Google Scholar
• HaraHOsakabeMKitajimaATamaoYKikumotoRMCI-9042, a new antiplatelet agent is a selective S2-serotonergic receptor antagonistThromb Haemost19916544154202057925
   PubMed Web of Science ®Google Scholar
• RashidMManivetPNishioHIdentification of the binding sites and selectivity of sarpogrelate, a novel 5-HT2 antagonist, to human 5-HT2A, 5-HT2B and 5-HT2C receptor subtypes by molecular modelingLife Sci200373219320712738034
   PubMed Web of Science ®Google Scholar
• YamashitaTKitamoriKHashimotoMWatanabeSGiddingsJCYamamotoJConjunctive effects of the 5HT(2) receptor antagonist, sarpogrelate, on thrombolysis with modified tissue plasminogen activator in different laser-induced thrombosis modelsHaemostasis200030632133211357001
   PubMedGoogle Scholar
• SainiHKTakedaNGoyalRKKumamotoHArnejaASDhallaNSTherapeutic potentials of sarpogrelate in cardiovascular diseaseCardiovasc Drug Rev2004221275414978517
   PubMedGoogle Scholar
• NohYLeeJShinSAntiplatelet therapy of cilostazol or sarpogrelate with aspirin and clopidogrel after percutaneous coronary intervention: a retrospective cohort study using the Korean national health insurance claim databasePLoS One2016113e015047526939062
   PubMed Web of Science ®Google Scholar
• ShinoharaYNishimaruKSawadaTS-ACCESS Study GroupSarpogrelate-Aspirin Comparative Clinical Study for Efficacy and Safety in Secondary Prevention of cerebral infarction (S-ACCESS): a randomized, double-blind, aspirin-controlled trialStroke20083961827183318388340
   PubMed Web of Science ®Google Scholar
• ParkSYRheeSYOhSEvaluation of the effectiveness of sarpogrelate on the surrogate markers for macrovascular complications in patients with type 2 diabetesEndocr J201259870971622673600
   PubMed Web of Science ®Google Scholar
• ShimizuTYamadaYTashitaAPharmacokinetic analysis of antiplatelet effect of sarpogrelate hydrochloride and its application to drug dosage regimen – modeling based on reversible inhibition of 5-HT2 serotonergic receptor in the platelet membrane by sarpogrelate hydrochloride and its metaboliteYakugaku Zasshi199911911850860 Japanese10590712
   PubMed Web of Science ®Google Scholar
• ChoDYBaeSHLeeJKKimYWKimBTBaeSKSelective inhibition of cytochrome P450 2D6 by sarpogrelate and its active metabolite, M-1, in human liver microsomesDrug Metab Dispos2014421333924167220
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration (FDA)Guidance for industry drug interaction studies-study design, data analysis, implications for dosing, and labeling recommendations Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM292362.pdfAccessed May 8, 2016
   Google Scholar
• European Medicines Agency (EMA)Guideline on the investigation of drug interactions Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/07/WC500129606.pdfAccessed May 8, 2016
   Google Scholar
• ParkJBBaeSKBaeSHOhESimultaneous determination of sarpogrelate and its active metabolite in human plasma by liquid chromatography with tandem mass spectrometry and its application to a pharmacokinetic studyJ Sep Sci2015381424925354353
   PubMed Web of Science ®Google Scholar
• Anplag^® (sarpogrelate hydrochloride) [package insert]OsakaMitsubishi Tanabe Pharma Corporation2012
   Google Scholar
• YangJSKimJRChoEHuhWKoJWLeeSYA novel simultaneous determination of sarpogrelate and its active metabolite (M-1) in human plasma, using liquid chromatography-tandem mass spectrometry: clinical applicationAnn Lab Med201535439139826131409
   PubMed Web of Science ®Google Scholar
• ZhangCWangLYangYValidated LC-MS/MS method for the determination of sarpogrelate in human plasma: application to a pharmacokinetic and bioequivalence study in Chinese volunteersJ Pharm Biomed Anal201053354655120399588
   PubMed Web of Science ®Google Scholar
• TakadaYTakadaAUranoTMCI-9042, the new selective antagonist of serotonergic (5-HT2A) receptorsCardiovasc Drug Rev1997152101121
   Google Scholar
• ChoDYBaeSHLeeJKEffect of the potent CYP2D6 inhibitor sarpogrelate on the pharmacokinetics and pharmacodynamics of metoprolol in healthy male Korean volunteersXenobiotica201545325626325268386
   PubMed Web of Science ®Google Scholar
• LuCSuriAShyuWCPrakashSAssessment of cytochrome P450-mediated drug–drug interaction potential of orteronel and exposure changes in patients with renal impairment using physiologically based pharmacokinetic modeling and simulationBiopharm Drug Dispos201435954355225264242
   PubMed Web of Science ®Google Scholar
• Rowland-YeoKJameiMYangJTuckerGTRostami–HodjeganAPhysiologically based mechanistic modelling to predict complex drug-drug interactions involving simultaneous competitive and time-dependent enzyme inhibition by parent compound and its metabolite in both liver and gut-the effect of diltiazem on the time-course of exposure to triazolamEur J Pharm Sci201039529830920025966
   PubMed Web of Science ®Google Scholar
• VandenBrinkBMFotiRSRockDAWienkersLCWahlstromJLPrediction of CYP2D6 drug interactions from in vitro data: evidence for substrate-dependent inhibitionDrug Metab Dispos2012401475321976621
   PubMed Web of Science ®Google Scholar
• ClarkeGO’MahonySMCryanJFDinanTGVerapamil in treatment resistant depression: a role for the P-glycoprotein transporter?Hum Psychopharmacol200924321722319212940
   PubMed Web of Science ®Google Scholar
• O’BrienFEDinanTGGriffinBTCryanJFInteractions between antidepressants and P-glycoprotein at the blood-brain barrier: clinical significance of in vitro and in vivo findingsBr J Pharmacol2012165228931221718296
   PubMed Web of Science ®Google Scholar
• RautioJHumphreysJEWebsterLOIn vitro p-glycoprotein inhibition assays for assessment of clinical drug interaction potential of new drug candidates: a recommendation for probe substratesDrug Metab Dispos200634578679216455806
   PubMed Web of Science ®Google Scholar
• MaoQUnadkatJDRole of the breast cancer resistance protein (BCRP/ABCG2) in drug transport – an updateAAPS J2015171658225236865
   PubMed Web of Science ®Google Scholar
• BalimanePVMarinoAChongSP-gp inhibition potential in cell-based models: which “calculation” method is the most accurate?AAPS J200810457758619082742
   PubMed Web of Science ®Google Scholar
• ArafatTArafatBAwadRAbu-AwwadADetermination of loperamide in human plasma and saliva by liquid chromatography-tandem mass spectrometryJ Chromatogr B Analyt Technol Biomed Life Sci20149728188
   PubMed Web of Science ®Google Scholar
• ErcegMCindricMPozaic FrketicLVertzoniMCetina-CizmekBReppasCA LC-MS-MS method for determination of low doxazosin concentrations in plasma after oral administration to dogsJ Chromatogr Sci201048211411920109288
   PubMed Web of Science ®Google Scholar
• YamashitaSTachikiHAnalysis of risk factors in human bioequivalence study that incur bioinequivalence of oral drug productsMol Pharm200961485919049413
   PubMedGoogle Scholar
• JameiMTurnerDYangJPopulation-based mechanistic prediction of oral drug absorptionAAPS J200911222523719381840
   PubMed Web of Science ®Google Scholar
• RodgersTLeahyDRowlandMPhysiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong basesJ Pharm Sci20059461259127615858854
   PubMed Web of Science ®Google Scholar
• SatohTTaylorPBosronWFSanghaniSPHosokawaMLa DuBNCurrent progress on esterases: from molecular structure to functionDrug Metab Dispos200230548849311950776
   PubMed Web of Science ®Google Scholar
• KimHJJeongESSeoKAGlucuronidation of a sarpogrelate active metabolite is mediated by UDP-glucuronosyltransferases 1A4, 1A9, and 2B4Drug Metab Dispos20134181529153723704698
   PubMed Web of Science ®Google Scholar
• KimTEKimJRJungJAPharmacokinetics of a new once-daily controlled-release sarpogrelate hydrochloride compared with immediate-release formulation and the effect of foodJ Clin Pharm Ther201439219219524325365
   PubMed Web of Science ®Google Scholar
• KimTEKimJRJungJAComparison of pharmacokinetics between sarpogrelate hydrochloride immediate-release formulation and controlled-release formulationInt J Clin Pharmacol Ther201351211411923073143
   PubMed Web of Science ®Google Scholar
• LeeSYKimJRJungJAMultiple-dose study to evaluate pharmacokinetics, pharmacodynamics, and safety in healthy subjects: a comparison of controlled-release sarpogrelate and immediate-release sarpogrelatePharmacology2015961–2687526089136
   PubMed Web of Science ®Google Scholar
• ChenJLiuDZhengXZhaoQJiangJHuPRelative contributions of the major human CYP450 to the metabolism of icotinib and its implication in prediction of drug-drug interaction between icotinib and CYP3A4 inhibitors/inducers using physiologically based pharmacokinetic modelingExpert Opin Drug Metab Toxicol201511685786825850339
   PubMed Web of Science ®Google Scholar
• EvansMVCrankWDYangHMSimmonsJEApplications of sensitivity analysis to a physiologically based pharmacokinetic model for carbon tetrachloride in ratsToxicol Appl Pharmacol1994128136448079352
   PubMed Web of Science ®Google Scholar
• ParrottNPaquereauNCoassoloPLavéTAn evaluation of the utility of physiologically based models of pharmacokinetics in early drug discoveryJ Pharm Sci200594102327234316136543
   PubMed Web of Science ®Google Scholar
• AbduljalilKCainTHumphriesHRostami–HodjeganADeciding on success criteria for predictability of pharmacokinetic parameters from in vitro studies: an analysis based on in vivo observationsDrug Metab Dispos20144291478148424989891
   PubMed Web of Science ®Google Scholar
• DamyTPoussetFCaplainHHulotJSLechatPPharmacokinetic and pharmacodynamic interactions between metoprolol and dronedarone in extensive and poor CYP2D6 metabolizers healthy subjectsFundam Clin Pharmacol200418111312314748763
   PubMed Web of Science ®Google Scholar
• FeldRWooMMLeighlNA clinical investigation of inhibitory effect of panobinostat on CYP2D6 substrate in patients with advanced cancerCancer Chemother Pharmacol201372474775524013574
   PubMed Web of Science ®Google Scholar
• HamelinBABouayadAMéthotJSignificant interaction between the nonprescription antihistamine diphenhydramine and the CYP2D6 substrate metoprolol in healthy men with high or low CYP2D6 activityClin Pharmacol Ther200067546647710824625
   PubMed Web of Science ®Google Scholar
• LessardEYessineMAHamelinBADiphenhydramine alters the disposition of venlafaxine through inhibition of CYP2D6 activity in humansJ Clin Psychopharmacol200121217518411270914
   PubMed Web of Science ®Google Scholar